195 results about "Protein expression" patented technology

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

The application relates to the technical field of biological medicine and fundus disease treatment, in particular to application of Acbd3 in treatment of fundus diseases. It is found that the mRNA expression level and the protein expression level of Acbd3 in the retina of a fundus disease model mouse are significantly higher than those of a control group. After an Acbd3 inhibitor is used, the inflammatory reaction and neuron apoptosis in the retina of the fundus disease model mouse are significantly relieved, abnormal activation of Muller cells and microglia cells can be reduced, and a damaged blood-retina barrier can be repaired.

Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

To provide novel methods and uses for increasing a yield of recombinant proteins in host cells, which are simple, efficient and suitable for use in industrial methods.SOLUTION: Provided is a method of increasing a yield of a protein of interest (POI) in an eukaryotic host cell, preferably a yeast, by overexpressing at least one polynucleotide encoding at least one transcription factor of the present invention, preferably Msn4 / 2. Further provided are a recombinant eukaryotic host cell for manufacturing the POI, the host cell being engineered to overexpress at least one polynucleotide encoding at least one transcription factor, as well as the use of the host cell for manufacturing the POI.SELECTED DRAWING: None

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The present invention relates to a method for preparing a MAGEA8-Fc transgenic plant. Through a platform using a tobacco plant, a recombinant protein MAGEA8-Fc, in which a human IgG Fc fragment is fused to a MAGEA8 protein, can be stably expressed. The method of the present invention enables high-level expression efficiency and stable protein production by introducing a target gene into a plant genome using an Agrobacterium binary vector. By directly isolating and purifying the recombinant protein from the transgenic tobacco plant, large-scale production can be easily achieved. Compared to conventional microbial or animal cell-based expression systems, the method provides economic efficiency and scalability, and thus can be usefully applied as a platform for producing fusion proteins.

The application relates to the technical field of biological medicine, and discloses application of a reagent for detecting CBS gene expression level in preparation of a breast cancer diagnosis and / or prognosis product. The nucleotide sequence of the CBS gene is shown as SEQ ID NO. 1, and the amino acid sequence of the encoded CBS protein is shown as SEQ ID NO. 2. The experimental results of the application show that the expression of the CBS protein in breast cancer tissues is significantly higher than that in paracancerous tissues, and the CBS protein can be used as a biomarker for breast cancer diagnosis. Meanwhile, the ROC curve evaluation of the CBS protein expression amount on the prognosis results of breast cancer patients shows that the AUC value reaches 0.841, which also shows that the CBS protein can be used as a marker for the prognosis of breast cancer patients, and the CBS protein has important diagnostic significance for the prognosis of breast cancer.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The present invention generally pertains to methods of cultivating cells and producing a recombinant protein of interest, such as dupilumab. In particular, the present invention pertains to the use of a fixed seed schedule to determine the expansion time of seed train unit operations for improved cell growth and protein titer. The protein produced by the fixed seed schedule, such as dupilumab, can be later subjected to lipase activity reduction methods.

This application provides a method and apparatus for optimizing the codon sequence of human albumin, belonging to the field of data processing technology. Addressing the current problems of low synthesis efficiency and scarcity of human albumin drugs, it allows for the grouping of large datasets of human albumin amino acid sequences. An improved genetic optimization algorithm is then used to optimize the corresponding messenger RNA item by item, ultimately obtaining the optimal second target messenger RNA. When using this second target messenger RNA for protein expression to obtain the target recombinant human albumin, the expression efficiency of the host Pichia pastoris cells can be maximized, significantly improving the current synthesis efficiency of recombinant human albumin and greatly alleviating the problem of human albumin drug scarcity.

The application discloses application of a genetic lineage tracing mouse model in regulation of myocardial cell transformation into osteoblasts, and belongs to the technical field of biotechnology.The tracing mouse model is induced to have myocardial calcification through high-dose steroids or myocardial infarction operation, the tracing mouse model expresses a label protein in myocardial cells of mammals, and the label protein expression in the myocardial cells is realized through a Cre / loxP system.The genetic lineage tracing mouse model provided by the application can be used for detecting myocardial cell transformation into osteoblasts, and can also be used for developing or screening drugs capable of preventing myocardial calcification or preparing products for developing or screening the drugs capable of preventing myocardial calcification.

The application discloses a novel double-carrier expression system for protein expression and a construction method and application thereof. The novel double-carrier expression system for protein expression comprises a first carrier containing a nucleotide sequence for coding a first functional domain of glutamine synthetase and a nucleotide sequence of light chain and heavy chain of a protein to be expressed; and a second carrier containing a nucleotide sequence for coding a second functional domain of glutamine synthetase and a nucleotide sequence of a ScFv sequence of the protein to be expressed, and an amino acid sequence of the glutamine synthetase is composed of the first functional domain and the second functional domain. By using the expression system, the transfection efficiency and screening efficiency are greatly improved, and the expression amount of the target protein is obviously increased.

The application provides a kind of based on digestive tract tissue protein expression abundance determination method and system, applied to digestive tract tissue image processing technical field. Including: based on the PVDF membrane image after color development of digestive tract tissue acquisition in vitro, contain at least one protein standard band and the protein band of multiple target proteins;When determining the presence of electrophoresis distortion according to the band of target protein standard, construct pixel space coordinate system;The target image is obtained by angle correction and linear repair to PVDF membrane image, and the protein band corresponding to multiple target proteins in target image is in horizontal alignment state under pixel space coordinate system;Determine the development area of each target protein in target image and the irregular region of interest wrapped the protein band corresponding to multiple target proteins, and for each target protein, the expression abundance of target protein is obtained by analyzing the development area and the irregular region of interest, and the accuracy of the protein expression abundance is higher.

The present disclosure relates to methods, devices and systems for exposing microorganisms or compositions comprising functional proteins to an oscillating electric field substantially free of a magnetic component in order to improve stress responses, survival and metabolite or protein production. In embodiments, a controller drives one or more insulated emitters with a true AC signal or pulsed DC signal, in stepped, swept or shuffled patterns of an electric field oscillating at one or more frequencies in the range 210 Hz to 99 kHz. Exposure to the field provides surmounting energy that enhances protein breathing, catalysis, and fundamental functions of multiprotein complexes including transcription factors and ribosomes, thereby improving stress resistance of microorganisms, their viability during fermentation, drying, storage, transport, and / or increasing production of functional or therapeutic proteins, metabolites or microbial lysates. The technology is applicable to manufacture of probiotics, therapeutics, metabolites, food, alcohol, feed and bioenergy, cosmetics, nutraceuticals and biopharmaceuticals..

The application discloses circular RNA and application thereof in pigeon trichomonad vaccine. The circular RNA comprises a coding element capable of encoding recombinant pigeon trichomonad AP33 or AP65 protein. The coding element has a sequence shown in SEQ ID NO. 1 or SEQ ID NO. 2 or a conservatively variant sequence thereof. The circular RNA can induce protein expression and generate high-level antibodies in an animal body. When the circular RNA is applied to the pigeon trichomonad vaccine, the circular RNA does not contain infectious worm component, can be degraded into nucleotides in the body, cannot be integrated into a host genome, has no risk for pigeons, can stimulate pigeons to generate a stronger immune response, including humoral immunity and cellular immunity, and can effectively resist parasitic infection. Meanwhile, the vaccine has high stability, the vaccine of the application can be prepared on a large scale through a molecular technology, and production cost is low.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

The present application belongs to the technical field of biomedicine, and provides a pharmaceutical composition for inhibiting NFKBIZ gene expression, and a use. The present application designs a double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, the present application verifies a use of a pharmaceutical composition formed by the conjugation of the described nucleic acid molecules and targeting ligand molecules in ophthalmic diseases. The pharmaceutical composition can solve the problems with existing small molecule immunomodulatory drugs of low delivery efficiency and poor therapeutic effect, providing small nucleic acid drugs having tissue-targeted delivery functions, and has the advantages of long duration of efficacy and low side effects. In addition, the pharmaceutical composition has simple ingredients, is easy to synthesize, and has good prospects for translational applications.

The application discloses a method for generating protein expression information based on tissue staining images, comprising: inputting a tissue staining image to be analyzed into a trained neural network model, and generating protein expression information of at least one protein channel through inference of the neural network model, wherein the neural network model is trained in the following manner: cross-modal feature alignment training is performed on a tissue feature coding network in a neural network model to be trained, so that tissue structure image features are aligned with protein expression image features, to obtain a trained tissue feature coding network; the trained tissue feature coding network and a decoding network in the neural network model to be trained are taken as the neural network model to be trained, and protein expression supervised training is performed, to obtain the trained neural network model. The application reduces complex experimental steps and equipment requirements, can significantly reduce experimental costs and improve the efficiency of obtaining protein expression information.

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

The present disclosure relates generally to recombinant microbial cells expressing heterologous proteins of interest. Accordingly, certain aspects of the present disclosure relate, inter alia, to recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the present disclosure are particularly suitable for use in the expression, production, and secretion of heterologous proteins.

This invention belongs to the field of biomedical materials technology, specifically disclosing a core-shell microneedle, a core-shell microneedle patch, its preparation method, and its application. Through structural design and carrier material optimization, this invention provides a core-shell microneedle with a programmed sequential release of tannic acid in the outer shell and verteporfen in the core layer, successfully matching the dynamic physiological rhythm of wound healing and ensuring effective wound repair. In vitro and in vivo biological evaluations have confirmed that the core-shell microneedle patch prepared using the core-shell microneedles of this invention possesses excellent antibacterial, antioxidant, and immune microenvironment-regulating abilities. It can effectively induce macrophage polarization towards the M2 type, specifically inhibit YAP protein expression, and significantly accelerate the closure process of infected wounds. From both upstream immune regulation and downstream fibrosis inhibition levels, it dually blocks the pathological scar formation pathway, ultimately achieving high-quality, scar-free regenerative repair of infected wounds.

The application relates to the technical field of rice breeding, and particularly discloses a mutant of a rice fragility regulation gene BC21, a protein, an expression vector and application thereof. The application of the gene BC21 in regulating rice fragility enables the regulation of rice fragility through the mutation of the BC21 gene. The gene BC21 has the nucleotide sequence shown in SEQ ID NO:1 and is numbered as Os06g0196600 in a Rice GenomeAnnotation Database. The gene BC21 numbered as Os06g0196600 in the Rice GenomeAnnotation Database is regulated to change the content of cellulose, hemicellulose and lignin in rice stalks and leaves, so that the regulation of rice fragility can be realized.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

This invention relates to the application of Gen-miR-1 as a KARS inhibitor in the preparation of antitumor and antifibrotic drugs. Specifically, it discloses the application of Gen-miR-1 in the prevention and / or treatment of cell proliferation and migration diseases, particularly suitable for the preparation of drugs for the prevention and / or treatment of tumors and myocardial fibrosis associated with high KARS protein expression. This invention clarifies the specific inhibitory effect of Gen-miR-1 on KARS, providing a novel therapeutic target and drug candidate molecule derived from traditional Chinese medicine for cell proliferation and migration diseases (tumors, fibrosis) targeting the KARS pathway, thus broadening the application scenarios of active ingredients in traditional Chinese medicine in the treatment of related diseases.

The application provides a non-inducible engineering strain for producing alpha-matrix and a construction method and application thereof. The engineering strain of the application is a recombinant Escherichia coli, which contains an expression regulatory element and a sucrose phosphorylase gene, and the expression regulatory element includes a PgapA-infC tandem promoter, a Plpp-infC tandem promoter or a PalsR-infC tandem promoter. The engineering strain can greatly shorten the protein expression period without adding an inducer, and the bacterial body after fermentation culture is ended is used as a whole cell catalyst to synthesize alpha-matrix by glycosylation reaction of a substrate hydroquinone and a sugar donor (such as sucrose), and the molar conversion rate of the substrate hydroquinone is high, and the engineering strain has an industrial application prospect.